Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer

BMC Cancer

Table 1 Univariate analysis to determine the association between covariates and patient-derived xenograft establishment

Variable	PDX establishment		OR (95% CI)	P-value
	No (n = 47)	Yes (n = 15)
Cancer type
Oral cavity cancer (ref)	27 (77.1%)	8 (22.9%)	1.181 (0.367–3.797)	0.780
Others	20 (74.1%)	7 (25.9%)	1.181 (0.367–3.797)	0.780
HPV infection
P16 negative or unknown (ref)	31 (72.1%)	12 (27.9%)	0.484 (0.119–1.967)	0.311
P16 positive	16 (84.2%)	3 (15.8%)	0.484 (0.119–1.967)	0.311
Method of tumor acquisition^a
Biopsy (ref)	0 (0%)	6 (100%)	0.015 (< 0.001–0.148)	0.010
Surgical resection	47 (83.9%)	9 (16.1%)	0.015 (< 0.001–0.148)	0.010
Site of sampling^a
Metastatic (ref)	0 (0%)	9 (100%)	0.007 (< 0.001–0.068)	0.002
Primary	47 (88.7%)	6 (11.3%)	0.007 (< 0.001–0.068)	0.002
Recurrence^a
Primary (ref)	47 (75.8%)	8 (12.9%)	83.842 (3.600–1951.715)	0.006
Recurrent	0 (0%)	7 (11.3%)	83.842 (3.600–1951.715)	0.006
Stage at tumor acquisition
Stage I–III (ref)	24 (85.7%)	4 (14.3%)	2.870 (0.798–10.314)	0.106
Stage IV	23 (67.6%)	11 (32.4%)	2.870 (0.798–10.314)	0.106

ISSN: 1471-2407